Literature DB >> 11673832

Co-localization of multiple ErbB receptors in stratified epithelium of oral squamous cell carcinoma.

R Bei1, G Pompa, D Vitolo, E Moriconi, L Ciocci, M Quaranta, L Frati, M H Kraus, R Muraro.   

Abstract

The expression of all four ErbB receptors was compared by immunohistochemistry, using receptor-specific polyclonal antisera, in 32 invasive, 11 in situ carcinomas, six benign lesions, and 22 samples of histologically normal mucosa adjacent to specimens of carcinoma originating from oral cavity epithelium. Among invasive and in situ carcinoma, EGFR expression was the most prevalent (in 29/32 and 8/11 cases, respectively) followed by ErbB2 (17/32 and 2/11) and ErbB4 (9/32 and 1/10), while ErbB3 was only detected in invasive tumours (12/32). Specific patterns included invasive tumours with expression of EGFR (8/32) or ErbB4 (1/32) alone, as well as different receptor combinations (EGFR+ErbB2, EGFR+ErbB4, EGFR+ErbB2+ErbB3, EGFR+ErbB2+ErbB4, and all four receptors). Simultaneous expression of three or four ErbB receptors correlated with tumour invasion (p=2.2x10(-4)) and localized in the intermediate epithelial cell layer of well and moderately differentiated tumours. No other significant correlation with clinico-pathological features was noticed. Some benign lesions and histologically normal mucosa adjacent to carcinomas showed weak immunostaining of EGFR (10/28), ErbB2 (4/28) or ErbB4 (3/28). By comparison, overexpression, as indicated by increased staining intensity, was observed in invasive tumours for EGFR (18/32), ErbB2 (8/32), ErbB4 (3/32), and ErbB3 (3/32). Statistical evaluation demonstrated a significant association of EGFR or ErbB2 overexpression with invasive carcinoma when compared with benign lesions and apparently normal epithelium (p=5.2x10(-7) and p=5x10(-3), respectively). Tumour-specific overexpression of ErbB receptors and their co-expression, most frequently involving EGFR and ErbB2, in the same cell layer of neoplastic epithelium, implicate receptor heterodimers in the pathogenesis of oral squamous carcinoma. Copyright 2001 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11673832     DOI: 10.1002/path.965

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  24 in total

1.  HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models.

Authors:  Dongsheng Wang; Guoqing Qian; Hongzheng Zhang; Kelly R Magliocca; Sreenivas Nannapaneni; A R M Ruhul Amin; Michael Rossi; Mihir Patel; Mark El-Deiry; J Trad Wadsworth; Zhengjia Chen; Fadlo R Khuri; Dong M Shin; Nabil F Saba; Zhuo G Chen
Journal:  Clin Cancer Res       Date:  2016-06-29       Impact factor: 12.531

2.  Proteolytic cleavage and phosphorylation of a tumor-associated ErbB4 isoform promote ligand-independent survival and cancer cell growth.

Authors:  Jorma A Määttä; Maria Sundvall; Teemu T Junttila; Liisa Peri; V Jukka O Laine; Jorma Isola; Mikala Egeblad; Klaus Elenius
Journal:  Mol Biol Cell       Date:  2005-10-26       Impact factor: 4.138

3.  Violacein, an indole-derived purple-colored natural pigment produced by Janthinobacterium lividum, inhibits the growth of head and neck carcinoma cell lines both in vitro and in vivo.

Authors:  Laura Masuelli; Fabrizio Pantanella; Giuseppe La Regina; Monica Benvenuto; Massimo Fantini; Rosanna Mattera; Enrica Di Stefano; Maurizio Mattei; Romano Silvestri; Serena Schippa; Vittorio Manzari; Andrea Modesti; Roberto Bei
Journal:  Tumour Biol       Date:  2015-10-13

4.  pEGFR-Tyr 845 expression as prognostic factors in oral squamous cell carcinoma: a tissue-microarray study with clinic-pathological correlations.

Authors:  Gabriella Aquino; Giuseppe Pannone; Angela Santoro; Giuseppina Liguori; Renato Franco; Rosario Serpico; Gianluca Florio; Alfredo De Rosa; Marilena Mattoni; Valentina Cozza; Gerardo Botti; Simona Losito; Francesco Longo; Stefania Staibano; Giovanni Cuda; Lorenzo Lo Muzio; Carolina Sbordone; Pantaleo Bufo; Anna Grimaldi; Michele Caraglia; Marina Di Domenico
Journal:  Cancer Biol Ther       Date:  2012-07-24       Impact factor: 4.742

Review 5.  The role of epidermal growth factor receptor in head and neck squamous cell carcinoma.

Authors:  Rebecca G Pomerantz; Jennifer Rubin Grandis
Journal:  Curr Oncol Rep       Date:  2003-03       Impact factor: 5.075

6.  Differential expression of fatty acid synthase (FAS) and ErbB2 in nonmalignant and malignant oral keratinocytes.

Authors:  Sabrina D Silva; Isabela W Cunha; Ana Lúcia C A Rangel; Jacks Jorge; Karina G Zecchin; Michelle Agostini; Luiz P Kowalski; Ricardo D Coletta; Edgard Graner
Journal:  Virchows Arch       Date:  2008-06-06       Impact factor: 4.064

Review 7.  The ERBB3 receptor in cancer and cancer gene therapy.

Authors:  G Sithanandam; L M Anderson
Journal:  Cancer Gene Ther       Date:  2008-04-11       Impact factor: 5.987

8.  Enhancement of erbB2 and erbB3 expression during oral oncogenesis in diabetic rats.

Authors:  Eleftherios Vairaktaris; Lambros Goutzanis; Stavros Vassiliou; Sofia Spyridonidou; Emeka Nkenke; Georgios Papageorgiou; Pashalis Strantzias; Andreas Lazaris; Christos Yapijakis; Efstratios Patsouris
Journal:  J Cancer Res Clin Oncol       Date:  2007-08-18       Impact factor: 4.553

Review 9.  ErbB receptors in the biology and pathology of the aerodigestive tract.

Authors:  Sarah Morgan; Jennifer R Grandis
Journal:  Exp Cell Res       Date:  2008-08-23       Impact factor: 3.905

10.  Biomolecular markers in cancer of the tongue.

Authors:  Daris Ferrari; Carla Codecà; Jessica Fiore; Laura Moneghini; Silvano Bosari; Paolo Foa
Journal:  J Oncol       Date:  2009-08-19       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.